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Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery systems, and im-
proved continuous glucose monitoring devices offer unprecedented opportunities to improve post-
prandial glucose (PPG) management and overall care for adults with insulin-treated diabetes. These
developments led the Endocrine Society to convene a working panel of diabetes experts in December
2018 to assess the current state of PPG management, identify innovative ways to improve self-
management and quality of life, and align best practices to current and emerging treatment and
monitoring options. Drawing on current research and collective clinical experience, we considered the
following issues for the;200million adults worldwide with type 1 and insulin-requiring type 2 diabetes:
(i) the role of PPG management in reducing the risk of diabetes complications; (ii) barriers preventing
effective PPGmanagement; (iii) strategies to reduce PPG excursions and improve patient quality of life;
and (iv) education and clinical tools to support endocrinologists in improving PPG management. We
concluded that managing PPG to minimize or prevent diabetes-related complications will require
elucidating fundamental questions about optimal ways to quantify and clinically assess the metabolic
dysregulation and consequences of the abnormal postprandial state in diabetes and recommend re-
search strategies to address these questions. We also identified practical strategies and tools that are
already available to reduce barriers to effective PPG management, optimize use of new and emerging
clinical tools, and improve patient self-management and quality of life.
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The relationship between poorly controlled glycemia and both macrovascular and micro-
vascular complications of diabetes is well established. Until recently, management efforts
have focused on lowering hemoglobin A1c (A1c) levels, with most targeting fasting plasma
glucose (FPG). In 2001, however, an American Diabetes Association (ADA) consensus meeting
established postprandial glucose (PPG) as a potentially distinct contributor to both A1c targets
and diabetes-related complications [1]. Subsequent evidence suggests that reducing PPG ex-
cursionsmay be equally ormore important than reducingFPG in achieving overall A1c goals and
in reducing risk of diabetes-related complications [2, 3]
Despite these developments, managing PPG remains one of the most challenging aspects
of diabetes care [4, 5]. An important advance occurred in 2014, with the International Di-
abetes Federation having issued specific guidelines on treating and assessing PPG excursions
in patients with diabetes [6]. However, to date, few patients with insulin-requiring diabetes
report satisfaction with available management strategies or clinical support tools [6, 7], and
few spend adequate time in their target blood glucose (BG) range [8]. Meanwhile, many
questions raised by the ADA consensus statement remain unanswered, including the relative
contributions of FPG and PPG to A1c and long-term complications, and ways in which PPG
excursions impact patients’ time-in-range (defined as 70 to 180 mg/dL), self-management,
and quality of life (QOL) [9].
Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery sys-
tems, and improved continuous glucose monitoring (CGM) devices offer unprecedented op-
portunities to improve PPG management and overall care for people with insulin-treated
diabetes, as well as new opportunities to understand and target PPG excursions specifically
[10]. For these reasons, the Endocrine Society convened a working panel of diabetes experts in
Washington, DC on 15 December 2018 to assess the state of PPG management, align best
practices to current and emerging treatment and monitoring options, and identify innovative
ways to address PPGmanagement to improve self-management and QOL for the;200 million
adults worldwide with insulin-requiring diabetes [11]. This patient population includes 30
million people with type 1 diabetes (T1D), including 1 million on pump therapy worldwide [12].
The remainder are people with advanced type 2 diabetes (T2D) or other forms of insulin de-
ficiency [13, 14].
Our discussion, summarized below, drew on current research and collective clinical ex-
perience to address the following issues and develop recommendations for adults with insulin-
requiring diabetes:
•Knowledge needed to define optimal PPG guidelines and goals
•Ways that improving PPG management can reduce risks of diabetes complications
•Barriers preventing effective PPG management
•Strategies to reduce PPG excursions and improve patient QOL
•Education and clinical tools to support endocrinologists managing PPG
1. PPG Dynamics and Biology
Overall glycemia results from the sum of basal and PPG exposure. CGM studies have
provided a clear understanding of the dynamics of postmeal BG control in healthy individuals,
with PPG peaking ;30 to 60 minutes after a meal starts, with maximum levels ,140 mg/dL.
BG levels generally normalize to preprandial levels after 2 to 3 hours, although it can take 5 to 6
hours after a meal for complete absorption of ingested carbohydrates [15–17]. The primary
factors determining PPG profile are: (i) insulin secretion, (ii) insulin action in stimulating
glucose uptake and suppressing glucose production, (iii) glucagon suppression, (iv) glucose
effectiveness in stimulating its own uptake and production, and (v) gastric emptying and
incretin hormones. Defects in many of these five factors can underlie postprandial hypergly-
cemia (PPH) in prediabetes and overt diabetes [18–23]. For patients with diabetes, the size,
composition, and timing of meals, preprandial glycemic level, comorbidities, and duration and
type of diabetes may also modulate this relatively complex network [24–28].
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2. Current Understanding of the Clinical and QOL Impact of
PPG Excursions
A. Clinical Data
PPG excursionsmay include both hyperglycemia and hypoglycemia. Hypoglycemia remains a
significant risk when prandial insulin is used to control PPG and can have multiple indirect
effects on glucose variability (GV) [29]. An important research and clinical focus has been
cardiovascular disease (CVD) effects of hypoglycemia such as arrhythmias, ECG changes,
adverse cardiovascular events, and mortality, as well as considerable patient distress [30,
31]. Fear of further hypoglycemia may lower adherence to recommended insulin and
sometimes other therapies, setting up a vicious cycle requiring higher insulin doses ac-
companied by “defensive eating” and weight gain [32]. Although such marked clinical and
psychological impact can potentially make hypoglycemia the limiting factor in achieving
postprandial goals, most outcome studies of PPG excursions have focused on PPH. Several
epidemiologic studies have shown a correlation between elevated postprandial BG values and
negative clinical outcomes, with the strongest being studies linking PPH in pregnancy to
macrosomia [33, 34] and population data supporting a relationship between PPH and CVD
[35]. However, the precise impact of PPH on diabetes-related complications remains unclear.
Evidence showing the impact of hyperglycemic excursions on nuclear cytokines and other
markers of oxidative stress and inflammation provide a cellular rationale for the distinctive
contribution of PPH.
To date, only a few clinical trials suggest that managing PPG excursions measurably
impacts diabetes-related complications, notably a large study involving Australian adoles-
cents with T1D that associated multi-injection insulin programs or pump therapy with
improved A1C and PPG levels along with reduced appearance of diabetic retinopathy [36]. In
contrast, the HEART-2D trial compared prandial to basal insulin therapy 21 days after acute
myocardial infarctions in persons with T2D and found lower daily mean PPG with prandial
insulin, but no associated practical or biological impact on A1c or cardiovascular events [37].
Additionally, clinical data are conflicted over the contribution of PPG to overall glycemia at
varying levels of A1c [38, 39].
B. Impact on QOL
Patients commonly attribute a diverse array of experiences to PPH, all included under the
umbrella term of QOL. These experiences include impaired well-being, negative mood
changes, disruptive life events (e.g., impaired sleep quality and fatigue), and disease-specific
impacts (e.g., diabetes distress) over both the long and short term. Patients with insulin-
requiring diabetes frequently report PPH episodes, saying they feel “miserable,” “sluggish,”
or “foggy-brained.” Concerns about both PPH and hypoglycemia are common in patients
using bolus insulin, as is frustration at readings that suggest failure to balance dietary
choices and/or physical activity with insulin intake [40]. Perceptions that blood sugar is too
high after meals can themselves exacerbate diabetes distress, fueling fear, anxiety, shame, or
hopelessness about the ability to manage BG. CGM is changing these dynamics by reducing
underdosing and overdosing concerns, but creating new anxieties when mealtime BG is not
adequately controlled despite best efforts.
Published studies about the relationship between PPH and the myriad experiences and
physical and cognitive symptoms lumped together as QOL are generally small, anecdotal,
and inconsistent, making it difficult to determine the extent and impact of any given factor.
Additionally, differences in diabetes type, diabetes duration, treatment modality, person-
ality, age, and comorbidities complicate head-to-head comparisons, as do varying definitions
of PPH and GV [41–45]. Studies of long-term impact of PPH on cognitive decline and de-
mentia are somewhat stronger. Rizzo et al. [46], for example, found a strong association
between mean amplitude glycemic excursions and global cognitive function in elderly adults
with T2D using CGM. Whether these results reflect PPG specifically is unclear, as is the
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direction of association. Other findings associating glucose peaks to dementia risk in people
with diabetes suggest a more direct link and the possibility of intervention [47].
3. Managing PPG Excursions
A. Lifestyle Modification
Patients who want to reduce or limit medication use with lifestyle interventions often find
existing options such as very low–calorie diets to be unrealistic or unsustainable [48, 49].
Severely carbohydrate-restricted diets can rapidly affect BG, but long-term efficacy remains
unclear, and risks of hyperglycemia and hypoglycemia can complicate treatment, especially
when combined with intensive exercise. In insulin-requiring diabetes, unawareness that
high-fat/high-protein foods need adequate insulin despite low carbohydrates may undermine
glycemic control [50, 51]. Additionally, many patients report being unable to follow ADA
exercise guidelines, often citing lack of time for 30 minutes of activity at least 5 days a week
[52, 53].
Potentially more achievable but equally effective lifestyle and behavioral tools may
provide viable alternatives (Table 1 [54–66]). Preliminary data suggest that simply eating
carbohydrates last in amealmaymore effectively regulate PPG and lower glucose excursions.
Three small studies, two involving T2D and the other prediabetes, found that eating protein
and/or vegetables first, followed 10 minutes later by carbohydrates, significantly reduced
both glucose and incremental glucose peaks compared with eating carbohydrates first or
eating all components together [54–56]. A study in children with T1D found that eating
protein and fat 15 minutes before carbohydrates lowered PPG and GV significantly more
than standardmeals [57]. Evidence grounded in the physiology of circadian rhythms suggests
that exclusively limiting food intake to a 6- to 8-hour daily window (a common recommen-
dation is 10:00 AM to 6:00 PM)may benefit body weight and cardiovascular health regardless of
macronutrients or portion sizes [67]. Several nutritional supplements, including viscous
fiber, ascorbic acid (vitamin C), and apple cider vinegar also appear to reduce postmeal
glucose levels [59, 60].
Some evidence also suggests that timing of exercise may be equally if not more important
than its amount or vigor [61]. One small study found that in non–insulin-using people with
T2D, 10 minutes or more of postprandial walking may lower the glycemic effect of evening
meals more than premeal exercise, effectively blunting PPG excursions [62]. Other studies
have shown similar benefits from moderate or high-intensity exercise 30 minutes to an hour
after eating [63].
B. Pharmacologic Management
Faster-acting insulins more closely mimicking physiologic action of endogenously secreted
insulinmay improvePPG control. In late 2017, theUSFood andDrugAdministration approved
fast-acting insulin aspart (Fiasp) for both T1D andT2D,with a 4.5-fold greater insulin exposure
in the first 15minutes than aspart insulin but comparable time tomaximum concentration and
total exposure, along with a greater glucose-lowering effect during the first 90minutes [68, 69].
Clinical studies on T1D showmodest improvement in A1c and PPG over conventional aspart,
with peak impact 1 hour after eating [70]. These findings, as well as the potential benefits of
faster acting insulin aspart in pump therapy, deserve further investigation.
Technosphere inhaled insulin also has a considerably faster absorption profile than do
conventional rapid-acting insulin analogs and improves PPG more effectively at 1 and 2
hours along with less late hypoglycemia when dosed appropriately. Although some patients
prefer the pulmonary formulation, optimal dosing can be challenging, and, as with all faster
acting insulins, cost limits usage. A study in T1D showed modest improvements over insulin
aspart in glucose control with accompanying weight loss, findings that deserve further study
[71]. Several ultra–rapid-acting insulins are in clinical development with even faster and
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shorter action profiles that more closely mimic the physiology of endogenously secreted
insulin, both for subcutaneous administration as well as oral/buccal, nasal, and pulmonary
routes, although most are unlikely to be available for another 5 to 10 years [72, 73].
Pramlintide, a synthetic form of amylin, has long been known to reduce PPG excursions
in adults with insulin-requiring diabetes. However, high risks of gastrointestinal side
effects and hypoglycemia, especially in T1D, limit clinical utility [74–77]. Although GLP-1
analogs are widely recognized as helpful in glycemic and weight control in patients with
T2D using basal insulin, randomized controlled trials of patients with T1D show neither
consistent nor sustained A1c reductions, with higher risks of severe hypoglycemia or
diabetic ketoacidosis (DKA). However, in both ADJUNCT ONE and TWO, liraglutide’s
effects on glycemic control were significantly better in C-peptide–positive patients com-
pared with patients with undetectable C-peptide, a finding deserving additional consideration
[78, 79].
Table 1. Lifestyle and Nutrition Approaches to Minimize Postprandial Excursions
Approach Recommendation
Explanation and Potential Impact on
PPG
Monitor PPG Monitor BG at 1 h and/or 2 h after meals by
fingerstick or CGM
Increasing BG monitoring after meals
(especially larger meals) will provide insight
into the need for a correction dose of
rapid-acting insulin. High-fat meals delay
stomach emptying and result in a later
timing of peak PPG values [58].
Take insulin before
eating
Leave enough time for insulin to start
working (“lag time”) before eating. This
is typically 20 min for analog insulins,
but considerably less with newer
ultra–rapid-acting insulins and/or if
BG is well controlled.
Taking insulin up to 30 min before meals with
analog insulin is more effective and
potentially safer in controlling mealtime
PPG than taking insulin right at, or after,
meals, a practice that can promote insulin
stacking if the person becomes frustrated
with initially high BG [64–66].
Carbohydrates last Eat nonstarchy vegetables and protein (e.g.,
fish, meat) first. Save carbohydrates and
starchy foods, including starchy vegetables
(e.g., potatoes, peas, yams), for last.
Several small studies of patients with either
T1D or T2D show that eating protein and
vegetables first reduces both PPG and
incremental glucose peaks significantly
more than eating carbohydrates first or
eating all components together [54–57].
Add supplements Consider taking vitamin C and fiber
supplements and adding apple cider
vinegar to meals.
Taking 500 mg of vitamin C (ascorbic acid)
twice daily has been shown to improve PPG
[60]. Viscous fibers, present in oat bran,
citrus fruits, and guar gum, b-glucan, and
psyllium supplements have also been found
to reduce postmeal sugars. Apple cider
vinegar, one teaspoon right before meals,
can reduce PPG, which is likely related to
acetic acid and the slowing stomach
emptying [59]. As vitamin C and vinegar are
acidic, brushing teeth is wise.
Exercise after
eating
Exercise moderately for 10 to 20 min within
an hour of eating. Moderate activity may
include brisk walking, using exercise
machines, or lifting light weights. If using
insulin or sulfonylureas with tightly
controlled BG, adjust the dose down
with the guidance of your provider.
A small study shows at least 10min of walking
after an evening meal may blunt PPG
excursions more than premeal exercise [62].
Other studies show similar benefits from
moderate or high-intensity exercise 30
minutes to an hour after eating [61, 63].
This table lists promising lifestyle and nutritional approaches to managing PPG that providers can suggest with T1D
or insulin-requiring T2D. Although evidence of efficacy and underlying mechanisms remains limited, these easy-to-
follow, low-cost, and low-risk approaches may be useful alternatives to less practical or sustainable dietary and
exercise regimens.
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Several recently completed phase 3 trials suggest that sodium-glucose cotransporter type 2
(SGLT2) inhibitors, commonly used as second-line therapies in T2D, improve both fasting and
postprandial glycemic control along with lowering blood pressure and weight loss without
increasing hypoglycemia in inadequately controlled T1D, althoughwith an increasedDKA risk
to 4% to 5% [80–82]. Recently completed phase 3 trials associated the investigational dual-
inhibitor combination drug sotagliflozin with sustained A1c reduction, weight loss, lower
insulin dose, improved patient-reported outcomes, and fewer episodes of severe hypoglycemia
when combined with optimized insulin therapy in T1D, particularly in patients with A1c
levels,7.0%. Risk of DKAwas significant, as with other SGLT2 inhibitors [82, 83]. Regulatory
approval of these agents for use as an oral adjunct to adjustable insulin in adults with T1D
varies by country, with none currently approved for this use in the United States.
4. Current and Emerging Management Technologies
A. CGM
By providing dynamic, real-time measures, CGM systems have contributed greatly to un-
derstanding PPG excursions along with overall patterns of glycemia. CGM systems measure
interstitial glucose concentration to provide wearers with real-time glucose readings and
trend arrows indicating the direction and rate at which glucose values change. By providing
this information in the context of historical data, CGM systems give wearers and their health-
care providers insight into current and retrospective trends. Patients using a CGM system
can see directly how and when different meal types, behaviors, exercise, and medications
affect PPG and adjust insulin timing and dose by combining glucose readings and trend arrow
data with insight into the time required for insulin absorption. CGM data also provide in-
formation to patients about the impact of insulin timing relative tomeal ingestion, improving
the potential to reduce both PPH and delayed hypoglycemia with postmeal dosing [64–66, 84,
85]. Studies of persons with type 1 diabetes using CGM have shown they spend more time-in-
range than do those receiving usual care, reducing both hyperglycemia and hypoglycemia,
and decreasing GV [86–88]. Improved glycemic control has also been shown in T2D [58].
The ability to analyze real-time data is a key advantage of CGM systems, expanding
patient and clinician understanding of glucose fluctuations, height and duration of PPG
excursions, and specific PPG profiles, as well as facilitating comparisons with normal glucose
physiology. CGM also makes it easier to predict effects of temporary changes in glucose
values onweekends vsweekdays or associatedwith events such asmenses, viral infections, or
short courses of steroids. By depicting effects of different meal types on PPG, CGM data have
also highlighted the need to consider dietary composition and quantity when counseling
patients and, in particular, to consider protein and fat as well as carbohydrate intake in
dosing calculations [50, 51, 89, 90]. This approach marks a revolutionary change in prandial
management, requiring a more holistic understanding of nutrition, gastrointestinal ab-
sorption, and insulin kinetics and action and opening the possibility of targeted interventions
personalized to factors including time of day, type of meal, physical activity, and stressors.
Managing the quantity and variety of information these devices provide remains chal-
lenging for both patients on insulin pump or multiple daily insulin (MDI) therapy and their
providers, however. We suggest that providers consider a stepped approach to reviewing and
interpreting reports, focusing on data sufficiency, CGMuse, time-in-range, andGV, as well as
ambulatory glucose profile and daily view [91]. Patients may require even more guidance
than their providers in interpreting data, as well as in using trend arrow data safely and
practically [92, 93], making certified diabetes educators who can demonstrate new devices
and help patients interpret CGM more valuable than ever [94].
B. Continuous Subcutaneous Insulin Infusion
Continuous subcutaneous insulin infusion (CSII, or insulin pump) therapy aims to mimic
normal insulin secretion by continuously infusing rapid-acting insulin at preselected rates,
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with patient-activated bolus doses at mealtimes or as corrections for hyperglycemia. Besides
bolus dose calculators that consider carbohydrate intake, current glucose concentration with
glucose target, and insulin on board, some devices include presets for differentmeal sizes, and
most provide options to extend insulin delivery over a specified time for high-protein or high-
fat meals or for patients with gastroparesis who require extending the prandial insulin dose
to match delayed digestion and food absorption.
Current and emerging CSII systems have considerably improved CGM integration and
insulin delivery options. A key advance has been low-glucose suspend and predictive low-
glucose suspend features that stop insulin delivery when glucose levels rapidly approach or
fall below a threshold level for hypoglycemia, for a preset period of time (2 hours with low-
glucose suspend), or with predictive low-glucose suspend until there is an increased glucose
trajectory as determined by the integrated CGM so the glucose level rises above the low
glucose threshold. Also important are hybrid closed-loop systems that automatically adjust
basal rates based on sensor readings but currently require patients to enter carbohydrate
intake manually for insulin boluses. Sophisticated downloads through CGM systems provide
data on glucose trends, including time in target range as well as hyperglycemia and hy-
poglycemia, glucose measurements by capillary testing, timing of insulin doses, and basal
rate changes, which help refine both insulin doses and patient behaviors. Reports provided by
CGM systems, such as daily or overlay reports, are providing new insight into an array of
“diabetes behavior pitfalls” that increase risks of hypoglycemia, PPH, or rapid, unpredictable
fluctuations between them [95–97], including insulin dosing during or aftermeals, inaccurate
carbohydrate counting, neglecting effects of protein and fat intake, overreliance on postmeal
correction doses, holding or delaying insulin doses for near-normal BG before a meal, and
multiple small corrective insulin boluses. Such problematic dosing behaviors remain the
biggest challenge to optimal PPG levels, even with hybrid closed-loop pumps. Fully auto-
mated closed-loop systems (artificial pancreases), the technologic answer (together with
better ultra–fast-acting insulins) to normalizing glucose, are being tested, but for the fore-
seeable future insulin dosing still requires careful analysis of BG patterns by clinician and
patient to determine guidelines for optimal decision making.
Despite CGM and increasingly sophisticated device features, dosing inconsistencies and
errors remain common. Current dosing algorithms rely on carbohydrate intake and sensor or
capillary glucose, but they do not fully account for many of the myriad factors that influence
PPG and ultimately GV. Dosing calculations neglect food composition, trend arrows, med-
ications, biological and emotional stressors, activity, environmental factors, and timing of
insulin delivery. Patients therefore may not see expected results from premeal insulin doses,
even when calculated correctly. Assumptions about active insulin time, insulin sensitivity,
carbohydrate ratios, timing of eating, and adjunctive noninsulin medications can also skew
calculations. Our long-term expectation is that dose calculators and decision support systems
will continue evolving to become more sophisticated and accurate using artificial intelligence
systems that learn a patient’s glucose responsiveness, and they will remain a key element of
intensive insulin treatment programs for many years. The ultimate goal is highly sophis-
ticated closed-loop dosing algorithms that remove the need for human input in basal
and prandial insulin dosing, although we expect that there will be considerable discussion
and scientific analysis to determine what patients will most benefit from this expensive and
advanced technology.
5. Needs and Recommendations
A. Defining Optimal PPG Guidelines and Goals
Lack of a consistent, practical, cost-effective, and accurate measure of PPG complicates the
assessment of clinical trials and, ultimately, effective management. Most studies of PPG or
PPH consider the impact of A1c or glycemic variability rather than that of sustained hy-
perglycemia causing oxidative stress, which may be a more direct measure of the impact of






/jes/article-abstract/3/10/1942/5581189 by guest on 16 April 2020
glucose fluctuations [98]. Studies of PPH specifically also fail to capture hypoglycemic pa-
thologies such as inflammation, arrhythmias, and coagulopathies as contributors to GV.
Some studies measure glucose levels 2 hours, others 1 hour, after a meal. One metric gaining
traction is the biomarker 1,5-anhydroglucitol (GlycoMark®), which has been negatively
associated with macrosomia and other negative outcomes in CVD and in women with T1D,
T2D, or gestational diabetes [33, 35]. The role of biomarkers in research will likely continue to
evolve with CGM and other new measurement technologies.
Assigning maximum allowable values at a single point in time to a process occurring over
several hours limits the usefulness of current guidelines in assessing and optimizing post-
meal BG control. Without proven dynamic parameters, intervention trials must use non-
rigorous surrogatemeasures of PPG such as nonphysiologicmeal or carbohydrate challenges.
CGMmay help refine definitions of PPH and establish tolerable limits, althoughwemust still
establish any added benefit of focusing on time-in-range in the postprandial state vs the full
24-hour period, and determine ideal parameters for postmeal time-in-range along with the
impact of factors such as diabetes type and duration, dietary composition and timing, eth-
nicity, and pharmaceuticals. Fully differentiating the impact of basal vs bolus interventions
will require sophisticated wider-ranging measures than BG alone, such as circulating me-
tabolites and biomarkers/mediators of cellular stress or damage, especially in the postmeal
state. Given these limitations, the committee thought that there is insufficient evidence to
advocate any specific criteria for optimal PPG control. Toward these ends, we recommend
rigorous CGM studies in well-characterized groups to address these issues:
• Identify optimal measurement methodology for clinical practice and research, estab-
lishing clear clinical definitions, goals, and relative predictive power for GV, PPH, and
delta and/or aggregate rises in prandial BG via short-term correlations and surrogate
outcomes (markers of oxidative stress and inflammation) as well as long-term “hard”
outcomes (adjudicated cardiovascular events or other end-organ complications).
• Identify an integrated definition of a healthy, nontoxic postprandial state that combines
BG with an extensive characterization of circulating metabolites, biomarkers, cytokines,
and novel factors.
B. PPH Management and Risks of Diabetes Complications
Determining the value of PPG control in minimizing diabetes-related complications was
perhaps the most important question we considered. Despite clear evidence that PPH ex-
acerbates oxidative stress and inflammation, it remains unclear whether controlling these
glycemic spikes affects the development or progression of microvascular or macrovascular
disease above that attributed to overall glycemia. Also, although our discussion was focused
on persons with insulin-requiring diabetes receiving intensive insulin programs, we expect
that the consequences of PPH will be similar regardless of the diabetes type and treatment.
Addressing this critical issue will require research based on innovative strategies that se-
lectively vary PPG values without A1c-based BG differences. A related issue is the impor-
tance of PPG control for preserving b-cell function in newly diagnosed T1D. The Diabetes
Control andComplications Trial showed thatMDI injections or CSII pump therapy preserved
C-peptide secretion better than standard therapy [99]. Given the potential for PPG spikes to
activate inflammation, we need studies to differentiate PPG control from overall BG control
in recent-onset T1D.
We also discussed the need to identify patient subgroups most amenable to specific in-
terventions, particularly given today’s faster-acting and safer insulins and CGM. Uncovering
predictive markers for better PPG responses to specific pharmacological or lifestyle inter-
ventions is becoming increasingly important in an era of personalized medicine. Studies of
intense PPG management vs standard control in persons at high risk for PPH-related mor-
bidity or mortality are particularly needed, with an expectation that these can be rapidly
translated into clinical practice. Patients receiving hematopoietic stem cell transplantation, for
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example, often experience severe PPH due to high-dose steroids [100], but the value of treating
PPH in this population to reduce infectious complications and mortality remains unexplored.
To address these questions, we recommend both short-term studies with surrogate markers
and long-term studies with adjudicated outcomes to:
•Clarify PPH’s contribution to A1c and diabetes complications.
•Confirm that using CGM and best available intervention strategies to control PPG re-
duces onset and/or progression of complications.
•Determine the value of intensive PPG control in preserving C-peptide in recent-onset T1D.
•Compare the impact of intense vs standard PPG control in people at high risk for PPH-
related morbidity or mortality.
C. Elucidating the Relationship Between PPG and QOL
Improving QOL will require using quantifiable measures to develop a more sophisticated
understanding of the relationship between PPG and GV on patients’ perceptions that make
up what is commonly termed QOL. Pressing research needs include determining how ex-
cessive, lengthy, or frequent PPH must be to affect QOL, as well elucidating the effects of
postmeal hypoglycemia. A particularly timely topic that worriesmany patients is how peak or
sustained hyperglycemia or hypoglycemia impacts the risk for dementia/cognitive decline.
Building the knowledge base and awareness of these issues will require behavioral and
pharmacological intervention studies to measure more meaningful physical and emotional
outcomes than simply “patient satisfaction,” including fear of hypoglycemia, insecurity about
managing glycemic changes, and concerns about dosing accurately. We specifically recom-
mend clinical intervention studies that:
• Include relevant and standardized QOL measures of emotional and physical outcomes.
• Identify whether sustained PPH vs rapid changes in glycemia up or downmost affect QOL.
•Clarify the relationship between postmeal hyperglycemia and hypoglycemia on quan-
tifiable and clinically understandable QOL parameters, and confirm the clinical pre-
dictive power of current assessment tools.
•Confirm the association between QOL and PPG control by showing that intervention trials
designed for better and more predictable postmeal BG control improve QOL parameters,
and, conversely, that specific QOL interventions are associated with improved PPG control.
D. Strategies to Reduce PPG Excursions
Safe, effective, and practical intervention strategies remain a pressing need in managing
PPG. Although providers and patients usually expect these to bemedications, we recommend a
closer look at a new array of behavioral and dietary options meshing with patient requests for
lifestyle and nutritional approaches to minimize medications, cost, and complexity. Clinicians
can describe these behavioral options using relatively simple messages that empower patients,
particularly when coupled with CGM. We also support continued efforts to develop novel
approaches to optimizing PPG control such as faster and smarter prandial insulins along with
exploring noninsulin pharmacological agents as adjunctive therapy, and alternative insulin
delivery (e.g., pulmonary) when dosed appropriately. Rigorous, carefully designed and moni-
tored trials are recommended to:
• Identify effective sustainable dietary and lifestyle approaches as adjunct therapy in insulin-
treated patients, elucidating underlying mechanisms and monitoring relevant clinical
outcomes, including weight and lipid control and BG predictability, together with PPG.
•Compare the value of several behavioral options in a stepwise fashion vs a single intervention.
•Critically examine current faster-acting insulins to identify patient characteristics, and
dosing and timing strategies, to optimize clinical benefits.
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•Determine long-term safety and best practices for using inhaled insulin.
•Continue searching for an ideal prandial insulin matching the kinetics of endogenous
prandial insulin, focusing on safety, efficacy, and meaningful clinical benefits.
•Determine cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 receptor
agonists in T1D, with particular emphasis on clarifying strategies to limit DKA risk.
•Analyze the safety and efficacy of GLP-1 agents as adjunctive therapy in C-peptide–
positive patients with T1D.
E. Optimizing Use of Clinical Tools to Improve Self-Management
As new and emerging technologies change day-to-day management decisions, clinicians
must provide substantial guidance in using them, including advanced training in pump use,
interpreting CGM data, and personalizing dosing instruction to include behavioral, dietary,
and exercise choices. Current CGM-regulated and nonautomated CSII systems demand a
focus on correct timing and dosing of bolus insulin. Trend arrow data, although a great
advance, can be overwhelmingly complex. In a move toward standardization, the Endocrine
Society recently convened two expert panels to develop approaches to adjusting rapid-acting
insulin doses for adults treated by MDI injections or nonautomated CSII using trend arrows,
based on individual insulin sensitivity and trend arrow direction [92, 93]. Many new tools and
phone apps are also in development or becoming available to improve self-management skills
for meal choice, calorie and carbohydrate counting, activity level, bolus adjustments, and
other self-care behaviors. Automated decision-support systems and “virtual coaches” using
artificial intelligence to analyze CGMdata allow patients to visualize effects of insulin dosing,
eating patterns, and physical activity in real time, enabling them to make both medical and
behavioral adjustments accordingly. Also of considerable interest are “smart pens” that can
track injection data, calculate doses, and share therapy data with caregivers and health-care
providers. We recommend the following steps to optimize patient and provider knowledge
about and use of these developing clinical tools:
•Provide access to CGM therapy to every patient with insulin-requiring diabetes on insulin
pump or MDI therapy, along with a standardized education program to optimize analysis
and utilization of trend arrows and other data.
•Continue developing advanced algorithms for “bolus calculators” that account for trend
arrows, macronutrient intake beyond carbohydrates, physical activity, and timing of
insulin delivery, incorporating inexpensive and accessible clinical decision-support de-
vices and phone apps.
6. Discussion
Managing PPG to minimize or prevent diabetes-related complications will require a deeper
understanding of fundamental questions about quantifying and clinically assessing the
metabolic dysregulation and other consequences of the abnormal postprandial state. We
particularly need more rigorously defined parameters for successful PPG management,
including amaximumallowable PPG value and the precise time tomeasure it. Growing use of
CGM should allow us to basemore useful goals on proven healthy criteria for time-in-range or
aggregate BG in the postprandial period. However, doing so will require extensive research
into what BG number or range, and at what frequency and over which length of time, is
associated with biologic damage and complications, and how factors such as disease type,
disease duration, meal size, meal composition, meal timing, or ethnicity affect these mea-
sures. We also must examine the effects of circulating lipids, amino acids, other metabolites,
and inflammatory factors in the postprandial state. Although we identified several promising
behavioral strategies that may have immediate clinical value, defining effective and sus-
tainable clinical strategies and tools for healthy PPG management calls for substantial
research addressing these basic questions.
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